Beta-TrCP-mediated Ubiquitination and Degradation of PHLPP1 Are Negatively Regulated by Akt

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2009 Oct 3

PMID 19797085

Citations 68

Authors

Xin Li

Jianyu Liu

Tianyan Gao

Affiliations

Soon will be listed here.

Abstract

PHLPP1 belongs to a novel family of Ser/Thr protein phosphatases that serve as tumor suppressors by negatively regulating Akt signaling. Our recent studies have demonstrated that loss of PHLPP expression occurs at high frequency in colorectal cancer. In this study, we identified PHLPP1 as a proteolytic target of a beta-TrCP-containing Skp-Cullin 1-F-box protein (SCF) complex (SCF(beta-TrCP)) E3 ubiquitin ligase in a phosphorylation-dependent manner. Overexpression of wild-type but not DeltaF-box mutant beta-TrCP leads to decreased expression and increased ubiquitination of PHLPP1, whereas knockdown of endogenous beta-TrCP has the opposite effect. In addition, we show that the beta-TrCP-mediated degradation requires phosphorylation of PHLPP1 by casein kinase I and glycogen synthase kinase 3beta (GSK-3beta), and activation of the phosphatidylinositol 3-kinase/Akt pathway suppresses the degradation of PHLPP1 by inhibiting the GSK-3beta activity. Furthermore, expression of a degradation-deficient PHLPP1 mutant in colon cancer cells results in a more effective dephosphorylation of Akt and inhibition of cell growth. Taken together, our findings demonstrate a key role for beta-TrCP in controlling the level of PHLPP1, and activation of Akt negatively regulates this degradation process.

Citing Articles

Modeling unveils sex differences of signaling networks in mouse embryonic stem cells.

Sultana Z, Dorel M, Klinger B, Sieber A, Dunkel I, Bluthgen N Mol Syst Biol. 2023; 19(11):e11510.

PMID: 37735975 PMC: 10632733. DOI: 10.15252/msb.202211510.

SKP2 Contributes to AKT Activation by Ubiquitination Degradation of PHLPP1, Impedes Autophagy, and Facilitates the Survival of Thyroid Carcinoma.

Shao Y, Ren W, Dai H, Yang F, Li X, Zhang S Mol Cells. 2023; 46(6):360-373.

PMID: 36694914 PMC: 10258456. DOI: 10.14348/molcells.2022.2242.

Chondrocytic and pharmacokinetic properties of Phlpp inhibitors.

Taylor E, Weaver S, Zars E, Turner C, Buhrow S, Reid J Osteoarthr Cartil Open. 2022; 3(3):100190.

PMID: 36474816 PMC: 9718091. DOI: 10.1016/j.ocarto.2021.100190.

Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.

Tan S, Spear R, Zhao J, Sun X, Wang P Front Genet. 2022; 13:905047.

PMID: 35832194 PMC: 9271851. DOI: 10.3389/fgene.2022.905047.

Potassium Effects on NCC Are Attenuated during Inhibition of Cullin E3-Ubiquitin Ligases.

Murali S, Little R, Poulsen S, Ferdaus M, Ellison D, McCormick J Cells. 2022; 11(1).

PMID: 35011657 PMC: 8750104. DOI: 10.3390/cells11010095.

References

Qiao M, Iglehart J, Pardee A . Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation. Cancer Res. 2007; 67(11):5293-9. DOI: 10.1158/0008-5472.CAN-07-0877. View

Manning B . Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol. 2004; 167(3):399-403. PMC: 2172491. DOI: 10.1083/jcb.200408161. View

Shaw R, Cantley L . Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441(7092):424-30. DOI: 10.1038/nature04869. View

Jia J, Zhang L, Zhang Q, Tong C, Wang B, Hou F . Phosphorylation by double-time/CKIepsilon and CKIalpha targets cubitus interruptus for Slimb/beta-TRCP-mediated proteolytic processing. Dev Cell. 2005; 9(6):819-30. DOI: 10.1016/j.devcel.2005.10.006. View

Brognard J, Sierecki E, Gao T, Newton A . PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell. 2007; 25(6):917-31. DOI: 10.1016/j.molcel.2007.02.017. View

Fuchs S, Spiegelman V, Kumar K . The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene. 2004; 23(11):2028-36. DOI: 10.1038/sj.onc.1207389. View

Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, Hunter T . M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci U S A. 2004; 101(13):4419-24. PMC: 384762. DOI: 10.1073/pnas.0307700101. View

Ferrarese A, Marin O, Bustos V, Venerando A, Antonelli M, Allende J . Chemical dissection of the APC Repeat 3 multistep phosphorylation by the concerted action of protein kinases CK1 and GSK3. Biochemistry. 2007; 46(42):11902-10. DOI: 10.1021/bi701674z. View

Gao T, Furnari F, Newton A . PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005; 18(1):13-24. DOI: 10.1016/j.molcel.2005.03.008. View

10.

Dorrello N, Peschiaroli A, Guardavaccaro D, Colburn N, Sherman N, Pagano M . S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science. 2006; 314(5798):467-71. DOI: 10.1126/science.1130276. View

11.

Cardozo T, Pagano M . The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol. 2004; 5(9):739-51. DOI: 10.1038/nrm1471. View

12.

Price M . CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling. Genes Dev. 2006; 20(4):399-410. DOI: 10.1101/gad.1394306. View

13.

Liu J, Weiss H, Rychahou P, Jackson L, Evers B, Gao T . Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene. 2008; 28(7):994-1004. PMC: 2921630. DOI: 10.1038/onc.2008.450. View

14.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

15.

Spiegelman V, Slaga T, Pagano M, Minamoto T, Ronai Z, Fuchs S . Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol Cell. 2000; 5(5):877-82. DOI: 10.1016/s1097-2765(00)80327-5. View

16.

Bloom J, Pagano M . Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003; 13(1):41-7. DOI: 10.1016/s1044-579x(02)00098-6. View

17.

Liu C, Kato Y, Zhang Z, Do V, Yankner B, He X . beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Natl Acad Sci U S A. 1999; 96(11):6273-8. PMC: 26871. DOI: 10.1073/pnas.96.11.6273. View

18.

Frame S, Cohen P . GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 2001; 359(Pt 1):1-16. PMC: 1222116. DOI: 10.1042/0264-6021:3590001. View

19.

Colaluca I, Tosoni D, Nuciforo P, Senic-Matuglia F, Galimberti V, Viale G . NUMB controls p53 tumour suppressor activity. Nature. 2008; 451(7174):76-80. DOI: 10.1038/nature06412. View

20.

Harrington L, Findlay G, Gray A, Tolkacheva T, Wigfield S, Rebholz H . The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004; 166(2):213-23. PMC: 2172316. DOI: 10.1083/jcb.200403069. View